Insulet

OverviewSuggest Edit

Insulet Corporation, a medical device company, develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The Company offers Omnipod Insulin Management System (Omnipod System), which consists of the OmniPod, an easy-to-use continuous insulin delivery system and Personal Diabetes Manager, a handheld wireless device. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas. Insulet Corporation sells and markets its Omnipod System through a combination of direct sales representatives and independent distributors.

TypePublic
Founded2000
HQActon, MA, USMap
Websiteinsulet.com
Overall CultureD+More
View Jobs (257)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)1,350(+16%)
Job Openings257
Revenue (FY, 2020)$904.4 M(+23%)
Share Price (Jul 2021)$278.6(+2%)
Cybersecurity ratingBMore

Key People/Management at Insulet

Shacey Petrovic

Shacey Petrovic

Director, President and Chief Executive Officer
Sally W. Crawford

Sally W. Crawford

Director
Charles Alpuche

Charles Alpuche

Executive Vice President and Chief Operating Officer
John Fallon

John Fallon

Director
Jim Hollingshead

Jim Hollingshead

Director
Bret Christensen

Bret Christensen

Executive Vice President and Chief Commercial Officer
Show more

Insulet Office Locations

Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 12 other locations
Acton, MA, US (HQ)
100 Nagog Park
Billerica, MA, US
600 Technology Park Dr #200
Charlotte, NC, US
Charlotte, NC, USA
Chicago, IL, US
Chicago, IL, USA
Columbus, OH, US
Columbus, OH, USA
Denver, CO, US
Denver, CO, USA
Show all (16)

Insulet Financials and Metrics

Insulet Revenue

Embed Graph
View revenue for all periods
Insulet's revenue was reported to be $904.4 m in FY, 2020
USD

Revenue (Q1, 2021)

252.3m

Gross profit (Q1, 2021)

167.5m

Gross profit margin (Q1, 2021), %

66.4%

EBIT (Q1, 2021)

16.3m

Market capitalization (1-Jul-2021)

18.4b

Closing stock price (1-Jul-2021)

278.6

Cash (31-Mar-2021)

820.7m

EV

17.6b
Insulet's current market capitalization is $18.4 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

152.3m211.4m247.1m288.7m324.2m367.0m463.8m563.8m738.2m904.4m

Revenue growth, %

17%12%13%

Cost of goods sold

85.5m119.0m134.7m145.4m176.1m155.9m186.6m193.7m257.9m322.1m

Gross profit

66.7m92.3m112.4m143.3m148.2m211.1m277.2m370.2m480.3m582.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

32.2m44.6m47.8m51.0m54.8m57.4m60.1m61.1m69.2m72.0m75.0m61.2m75.6m87.3m81.2m87.3m94.9m101.7m109.8m121.8m123.6m124.3m151.1m159.6m177.1m192.1m1.5m226.3m500.0k252.3m

Cost of goods sold

17.7m26.0m27.5m28.7m30.4m32.2m33.3m33.7m36.4m36.2m36.9m28.4m41.2m51.7m37.2m36.9m39.2m42.3m45.1m48.2m47.8m42.2m49.1m52.9m60.7m69.0m71.1m83.8m82.2m84.8m

Gross profit

14.5m18.6m20.3m22.3m24.4m25.2m26.8m27.4m32.8m35.8m38.0m32.8m34.4m35.7m44.1m50.5m55.6m59.4m64.6m73.6m75.8m82.1m102.0m106.7m116.4m123.1m(69.6m)142.5m(81.7m)167.5m

Gross profit Margin, %

45%42%43%44%45%44%45%45%47%50%51%54%45%41%54%58%59%58%59%60%61%66%67%67%66%64%(4640%)63%(16340%)66%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

94.0m57.3m149.7m151.2m122.7m137.2m272.6m113.9m213.7m907.2m

Accounts Receivable

23.2m33.3m33.1m39.9m48.4m28.8m53.4m63.3m69.3m83.8m

Prepaid Expenses

3.7m4.5m5.9m4.0m5.7m9.9m24.3m31.1m

Inventories

11.8m14.9m9.5m13.1m14.0m35.5m33.8m71.4m154.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

106.7m103.8m83.0m70.1m63.4m148.1m150.9m153.9m145.6m175.5m146.4m145.6m145.1m145.5m111.6m75.7m215.4m76.0m73.5m102.2m203.1m136.2m126.6m129.3m119.9m419.9m201.4m779.1m838.1m820.7m

Accounts Receivable

20.4m17.3m26.2m25.6m30.1m31.1m33.7m34.5m36.7m41.8m47.1m36.1m31.8m31.8m40.5m38.7m38.5m40.6m37.8m47.2m50.4m49.7m70.0m68.7m67.0m65.1m80.1m85.4m97.9m

Prepaid Expenses

4.8m3.7m3.5m4.3m5.6m6.4m6.6m5.9m7.1m5.7m3.4m3.7m3.4m4.0m5.7m6.8m7.9m8.2m8.4m8.0m17.4m17.6m17.9m28.0m25.2m20.7m43.9m59.6m53.4m73.6m

Inventories

16.0m13.1m14.7m16.4m15.1m9.2m6.0m5.4m10.4m8.8m9.7m20.1m23.4m13.0m14.0m24.5m32.7m34.3m34.0m35.1m26.3m40.8m58.1m73.8m85.1m90.2m95.7m103.7m124.9m170.1m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(45.8m)(51.9m)(45.0m)(51.5m)(73.5m)(28.9m)(26.8m)3.3m11.6m6.8m

Depreciation and Amortization

8.5m11.0m11.8m12.2m15.8m13.8m15.1m15.6m27.9m55.4m

Inventories

1.9m(3.0m)5.4m(3.6m)(722.0k)(24.1m)1.7m(38.8m)(30.2m)(50.5m)

Accounts Payable

7.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(29.3m)(42.8m)(14.8m)(29.3m)(41.7m)(10.7m)(21.2m)(42.5m)(6.1m)(35.3m)(46.1m)(11.8m)(27.3m)(46.2m)(12.5m)(16.7m)(19.8m)(10.0m)(17.7m)(20.0m)(6.6m)(8.3m)(6.6m)4.4m5.8m6.6m(2.1m)12.3m23.9m

Depreciation and Amortization

2.8m5.7m2.8m5.5m8.1m2.9m5.8m8.9m3.1m6.1m9.2m3.4m7.1m11.4m3.4m6.8m10.5m3.3m6.7m10.5m3.5m7.9m11.3m5.1m11.0m18.8m9.7m18.8m29.7m12.8m

Inventories

(2.2m)594.0k(2.9m)(4.6m)(3.3m)5.7m8.9m9.5m(985.0k)699.0k(198.0k)(7.0m)(10.3m)312.0k(2.6m)(13.1m)(21.3m)1.2m1.5m428.0k6.7m(8.0m)(25.3m)(2.7m)(14.0m)(20.0m)4.8m(2.8m)(22.9m)(17.9m)

Accounts Payable

2.2m1.9m
show all
USDQ2, 2011

Financial Leverage

2.4 x
Show all financial metrics

Insulet Operating Metrics

FY, 2016

Patents Issued

23

Patents Pending

32
Show all operating metrics

Insulet Revenue Breakdown

Embed Graph

Insulet revenue breakdown by business segment: 62.6% from U.S. Omnipod, 19.6% from International Omnipod and 17.8% from Drug Delivery

Insulet Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

Learn more about our premium products
SecurityScorecard logo

Insulet Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Insulet Online and Social Media Presence

Insulet's Trends

Embed Graph

Insulet Company Culture

  • Overall Culture

    D+

    62/100

  • CEO Rating

    D

    60/100

  • Compensation

    C+

    68/100

  • Diversity

    D

    57/100

Learn more on Comparably

Insulet News and Updates

May 24, 2021

Global Insulin Pens, Syringes, Pumps and Injectors Market 2021-2030 with Novo Nordisk A/S, Eli Lilly and Co, Medtronic, Abbott, and Insulet Dominating

Dublin, May 24, 2021 (GLOBE NEWSWIRE) -- The "Insulin Pens, Syringes, Pumps and Injectors Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering. Major players in the insulin pens, syringes, pumps and injectors market are Nov…
November 24, 2020

Infusion Pumps Market Growth & Revenue 2020 to 2025 | Smith Medical, Moog, ICU Medical, Insulet

Volumetric pumps are driving the market for infusion pumps over the forecast period, in the type segment Posted via Industry Today. Follow us on Twitter @IndustryToday
February 19, 2020

Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care

ABBOTT PARK, Ill. and ACTON, Mass., Feb. 19, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) and Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), announced today they are partnering to integrate...
November 25, 2019

lobal Artificial Pancreas Systems Market Report 2019 Top Key Players- Medtronic, Johnson and Johnson, Dexcom, Insulet, Tandem Diabetes Care and more...

A new market study, titled “Global Artificial Pancreas Systems Market Report 2019 - Market Size, Share, Price, Trend and Forecast”, has been featured on WiseGuyReports. Posted via Industry Today. Follow us on Twitter @IndustryToday
November 20, 2019

Why Is Insulet Stock Up More Than 15% Over The Last Month?

Insulet (NASDAQ: PODD), a company best known for selling the Omnipod continuous insulin delivery system that caters to people with diabetes, has seen its stock price rally by close to 17% over the last month. There have been multiple factors driving the rally. Firstly, the company posted stronger...
December 24, 2018

Medication Telemanagement Devices Market 2018 Global Analysis By Key Players – Abiogenix, Adherium, IA Collaborative, Insulet, MedFolio

Wiseguyreports.Com adds “Medication Telemanagement Devices Market –Market Demand, Growth, Opportunities, Analysis of Top Key Players and Forecast to 2025” To Its Research Database. Posted via Industry Today. Follow us on Twitter @IndustryToday
Show more

 Insulet Frequently Asked Questions

  • When was Insulet founded?

    Insulet was founded in 2000.

  • Who are Insulet key executives?

    Insulet's key executives are Shacey Petrovic, Sally W. Crawford and Charles Alpuche.

  • How many employees does Insulet have?

    Insulet has 1,350 employees.

  • What is Insulet revenue?

    Latest Insulet annual revenue is $904.4 m.

  • What is Insulet revenue per employee?

    Latest Insulet revenue per employee is $669.9 k.

  • Who are Insulet competitors?

    Competitors of Insulet include Tandem Diabetes Care, Genteel and POPS! Diabetes Care.

  • Where is Insulet headquarters?

    Insulet headquarters is located at 100 Nagog Park, Acton.

  • Where are Insulet offices?

    Insulet has offices in Acton, Billerica, Charlotte, Chicago and in 12 other locations.

  • How many offices does Insulet have?

    Insulet has 16 offices.